These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6408891)

  • 1. Lack of stimulation of antipyrine and phenytoin metabolism by lithium carbonate in man.
    Perrild H; Hansen JM; Skovsted L; Simonsen K; Hegedüs L; Christensen LK
    Acta Pharmacol Toxicol (Copenh); 1983 Apr; 52(4):315-7. PubMed ID: 6408891
    [No Abstract]   [Full Text] [Related]  

  • 2. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
    Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
    Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: Antipyrine half life and clearance in clinical practice.
    Whitling B; Ullah M; Meredith PA
    Br Med J; 1976 Aug; 2(6033):471. PubMed ID: 953613
    [No Abstract]   [Full Text] [Related]  

  • 4. Interaction between metronidazole and drugs eliminated by oxidative metabolism.
    Jensen JC; Gugler R
    Clin Pharmacol Ther; 1985 Apr; 37(4):407-10. PubMed ID: 3979002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test.
    Neuvonen PJ; Tokola RA; Kaste M
    Eur J Clin Pharmacol; 1981; 21(3):215-20. PubMed ID: 7318881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of drug metabolism by disulfiram in man.
    Vesell ES; Passananti GT; Lee CH
    Clin Pharmacol Ther; 1971; 12(5):785-92. PubMed ID: 4936142
    [No Abstract]   [Full Text] [Related]  

  • 7. Unaltered metabolism of phenytoin in thyroid disorders.
    Mølholm Hansen J; Skovsted L; Kampmann JP; Lumholtz BI; Siersbaek-Nielsen K
    Acta Pharmacol Toxicol (Copenh); 1978 May; 42(5):343-6. PubMed ID: 581029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
    Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
    Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No impairment of antipyrine elimination by the selective anticholinergic drug pirenzepine.
    Paxton JW; Foote SE; Paton DM
    Digestion; 1983; 27(1):44-6. PubMed ID: 6688400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hydroxylation of drugs- a pharmacogenetic problem?
    Evans DA
    Proc R Soc Med; 1970 Feb; 63(2):178. PubMed ID: 4191705
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
    Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H
    Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of drugs in rabbits with experimental acute renal failure.
    Van Peer A; Belpaire F; Bogaert M
    Pharmacology; 1978; 17(6):307-14. PubMed ID: 733890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic factors in hepatic drug oxidation.
    Kalow W; Inaba T
    Prog Liver Dis; 1976; 5():246-58. PubMed ID: 775542
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction between phenytoin and dichloralphenazone [proceedings].
    Riddell JG; Salem SA; McDevitt DG
    Br J Clin Pharmacol; 1980 Jan; 9(1):118P. PubMed ID: 7356880
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction between vigabatrin and phenytoin.
    Rimmer EM; Richens A
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):27S-33S. PubMed ID: 2757906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between antipyrine and aminopyrine.
    Vesell ES; Passananti GT; Hepner GW
    Clin Pharmacol Ther; 1976 Dec; 20(6):661-9. PubMed ID: 991537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolism of phenobarbitone, phenytoin and antipyrine in Black patients.
    Buchanan N; Bill P; Moodley G; Eyberg C
    S Afr Med J; 1977 Aug; 52(10):394-5. PubMed ID: 897846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation of microsomal mixed function oxidase(s) and human lung cancer.
    Kellermann G; Jett JR; Luyten-Kellermann M; Moses HL; Fontana RS
    Cancer; 1980 Mar; 45(6):1438-42. PubMed ID: 7357525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in uraemic rabbits.
    Van Peer AP; Belpaire FM; Bogaert MG
    J Pharm Pharmacol; 1980 Feb; 32(2):135-6. PubMed ID: 6103036
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in rabbits with experimental renal failure.
    van Peer AP; Belpaire FM; Bogaert MG
    Arch Int Pharmacodyn Ther; 1978 Aug; 234(2):346-7. PubMed ID: 708161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.